Cilibac

Cilibac is a broad-spectrum β-lactam/β-lactamase inhibitor combination that provides powerful antibacterial coverage against a wide range of Gram-positive and Gram-negative pathogens, including resistant strains producing β-lactamase enzymes.
It is indicated for serious infections in hospitals and clinics, ensuring rapid bacterial eradication and reliable patient outcomes.

• Broad-Spectrum Action – Effective against mixed and resistant infections
• Fast Clinical Response – Rapid onset with proven efficacy
• β-Lactamase Protection – Tazobactam prevents enzyme-mediated resistance

• Hospital-Grade Reliability – Trusted in critical and post-surgical infections

• Piperacillin is a broad-spectrum penicillin antibiotic that inhibits bacterial cell wall synthesis, leading to cell lysis and death.

• Tazobactam acts as a β-lactamase inhibitor, protecting Piperacillin from enzymatic degradation by resistant bacteria.
  Together, they deliver synergistic action against both β-lactamase–producing and non–β-lactamase–producing strains.

• Broad-Spectrum Coverage: Active against Gram+ & Gram– pathogens, including Pseudomonas aeruginosa.

• Resistance Control: Tazobactam enhances Piperacillin’s effectiveness against β-lactamase producers.

• Fast Bacterial Clearance: Rapid onset ensures early clinical improvement.

• Critical Care Utility: Effective for hospital-acquired and polymicrobial infections.

• Lower respiratory tract infections (including pneumonia)

• Urinary tract infections (complicated and uncomplicated)

• Intra-abdominal infections

• Skin and soft tissue infections

• Bone and joint infections

• Gynecological and pelvic infections

• Septicemia and febrile neutropenia

•  

• Conduct sensitivity testing before initiating therapy.

• Adjust dosage in patients with renal impairment.

• Use under medical supervision in pregnancy and lactation.

Generally well-tolerated when used as prescribed.
Common side effects may include mild diarrhea, nausea, headache, or rash.
Occasionally, allergic reactions, elevated liver enzymes, or local injection site irritation may occur.
Rarely, hypersensitivity reactions or thrombocytopenia may develop in susceptible patients.

• Adults: 4.5 g every 6–8 hours by IV infusion (administered over 30 minutes) or as directed by the physician.

• Children: Dosage adjusted according to body weight and clinical condition.

• Route: Intravenous use only.